Market Place
Sourcing Support
Emergex Changes Name To “Gylden Pharma Limited” For Expansion
17 Oct 2024 //
GLOBENEWSWIRE
Emergex Vaccine Candidate Selected by NIH/NIAID for Trials
02 Oct 2024 //
GLOBENEWSWIRE
Emergex Gets Patent For Long-Term T Cell Immunity Influenza Vaccines
22 Aug 2024 //
GLOBENEWSWIRE
Emergex Announces MHRA Approval For Manufacturing And Import License
18 Jun 2024 //
GLOBENEWSWIRE
Emergex Announces R&D Collaboration with DEKA Research & Development Corp.
16 Jan 2024 //
GLOBENEWSWIRE
Transfer of NDA from Former Zosano Pharma to Emergex for Drug Delivery Patch
18 Dec 2023 //
GLOBENEWSWIRE
Emergex Signs Contract of £1.79M with UK Department of Health and Social Care
17 Nov 2023 //
GLOBENEWSWIRE
Emergex and Saudi Arabia`s VIC have Signed MoU
05 Oct 2023 //
GLOBENEWSWIRE
Emergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP
19 Jul 2023 //
GLOBENEWSWIRE
Emergex Generates Chikungunya Ligandome
28 Nov 2022 //
GLOBENEWSWIRE
Bankrupt Zosano sells intradermal delivery tech to Emergex
18 Oct 2022 //
FIERCEPHARMA
Emergex Acquires Intradermal & Patch Drug Delivery Technology
12 Oct 2022 //
GLOBENEWSWIRE
Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine
27 Jul 2022 //
GLOBENEWSWIRE
Emergex Vaccines signs Heads of Terms for a Collaboration with IBMP, Brazil
01 Jul 2022 //
GLOBENEWSWIRE
Emergex Coats its CD8+ T cell Adaptive Vaccine onto Zosano`s Micro-Needle Patch
17 May 2022 //
GLOBENEWSWIRE
Emergex: Studies of Novel Dengue Fever and Coronavirus T cell Adaptive Vaccines
18 Apr 2022 //
GLOBENEWSWIRE
Emergex Advances Vaccine Candidate for Tularemia
14 Apr 2022 //
GLOBENEWSWIRE
Emergex Signs Agreement with ATCC for Yellow Fever Booster Vaccine Candidate
06 Apr 2022 //
GLOBENEWSWIRE
Emergex Awarded £490,525 Aid Grant by the Department of Health and Social Care
22 Feb 2022 //
GLOBENEWSWIRE
NanoPass`s intradermal delivery platform used in Emergex`s vaccination study
26 Jan 2022 //
PRNEWSWIRE
Emergex T-Cell Priming COVID Vax Candidate Holds Potential Against Omicron
30 Nov 2021 //
CONTRACTPHARMA
Emergex obtains approval to commence Phase I trial of Covid-19 vaccine
16 Nov 2021 //
CLINICALTRIALSARENA
Emergex announces approval to initiate Phase I clinical trial
15 Nov 2021 //
GLOBENEWSWIRE
Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue
30 Jun 2021 //
GLOBENEWSWIRE
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos
04 Jan 2021 //
GLOBENEWSWIRE
Emergex Vaccines Forms US Subsidiary (Emergex USA)
31 Aug 2020 //
BUSINESSWIRE
Emergex and Bio-Manguinhos/Fiocruz Elucidate T Cell Epitopes Produced
19 Aug 2020 //
BUSINESSWIRE
Emergex and Bio-Manguinhos/Fiocruz Elucidate T Cell Epitopes
19 Aug 2020 //
BUSINESSWIRE
Emergex Signs Agreement with GEORGE MASON UNIVERSITY for Highly Pathogenic RNA
22 Apr 2020 //
BUSINESSWIRE
Aro Biotherapeutics and Ionis Enter Licensing and Collaboration Agreement
09 Jan 2020 //
BUSINESS WIRE
Emergex completes £8.4m Series A vaccines funding
08 Jan 2020 //
PHARMA TIMES
Emergex completes £8.4m Series A vaccines funding
07 Jan 2020 //
PHARMA TIMES
Emergex completes £8.4m Series A vaccines funding
07 Jan 2020 //
PHARMA TIMES
